Gapping up
In reaction to earnings/guidance:
- ATKR +11.6%, HLIT +8.3%, CC +7.2%, CAR +6.9%, AMRC +6.1%, CDLX +6%, VNOM +5.8%, MED +5.3%, GEO +5.2%, NTR +5.1%, CACC +5%, BP +4.8%, MPWR +4.7%, ESPR +4.7%, CTLT +4.3%, AME +4%, SANM +3.8% (also increases buyback authorization by $200 mln), CTRA +3.6%, PEG +3.5%, IPI +3.4%, OTTR +3.4%, NTB +3.2%, LPX +3.2%, OHI +3.1%, CMS +3%, WMB +2.8%, VSH +2.8%, DVN +2.6% (also raises dividend by 27% and expands share buyback auth), ETRN +2.5%, AGCO +2.5%, NRZ +2.4%, HWM +2.3%, LEG +2.2%, VAL +2.1%, TRTN +1.8%, VNO +1.6%, WLK +1.6%, NXPI +1.5%, SEDG +1.5%, FIS +1.5%, MPLX +1.2%, DK +1.2%, AGNC +1.1%, EXPE +1.1%, BIGC +1.1%, AQUA +1%
Other news:
- BLTE +14.1% (announces that LBS-008 an orally administered tablet has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of STGD1)
- ASTS +12.1% (receives experimental license from FCC for BlueWalker 3 satellite testing)
- STOK +6.7% (presents new in-vivo data)
- TSHA +5.6% (granted orphan drug designation from the European Commission for TSHA-120)
- LMDX +5% (stock offering)
- GNW +3.2% ($350 mln share repurchase auth)
- IMO +1.6% (announces terms of its substantial issuer bid for up to CAD2.5 bln)
- CCL +1.2% (celebrates restart of entirety of Carnival Cruise Line fleet)
- MPLX +1.2% (Whistler Pipeline expansion reaches final investment decision)
- ACAD +1% (FDA Advisory Committee to host meeting to review sNDA for NUPLAZID on June 17)
Analyst comments:
- API +4.2% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- JAKK +3.8% (upgraded to Outperform from Market Perform at BMO Capital Markets)
- ARGX +2.6% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SHEN +2.6% (upgraded to Strong Buy from Outperform at Raymond James)